Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3BNC117 + 10-1074
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
3BNC117 + 10-1074 is a combination of two broadly neutralizing monoclonal antibodies (bNAbs) under investigation for the prevention and treatment of HIV-1 infection. Both antibodies target non-overlapping epitopes on the HIV-1 envelope glycoprotein, with 3BNC117 binding to the CD4 binding site and 10-1074 targeting the V3 glycan-dependent epitope. This dual targeting aims to enhance antiviral efficacy and reduce the risk of resistance compared to monotherapy. The combination has been shown in clinical trials to be safe, generally well tolerated, and effective at suppressing viral load during analytical treatment interruption in people living with HIV. It is being developed as a long-acting injectable for both pre-exposure prophylaxis (PrEP) and therapeutic use in individuals with HIV[5][6][7].
- Other names
- broadly neutralizing antibodies-IrsiCaixa-HIV infectionbNAbs-IrsiCaixa3BNC117 and 10-1074 combination
02
Targets
gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)V3 glycan patch (HIV-1 gp120 V3 glycan patch)
Beyond the preview
Go deeper on 3BNC117 + 10-1074.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3BNC117 + 10-1074.